검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Liposomal doxorubicin |
Overview Company | Palleos Healthcare GmbH |
Overview Modality | ADC |
Overview Target | Breast Neoplasms |
Overview Indication | Lymphoproliferative Disorder; HHV-8 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | , Clinical and Translational Science |
MoA Biomarker | biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study |
PK/PD Half-life | 3 h |
PK/PD Species | Mouse, Rat, Study objectives were safety, response, survival, and pharmacokinetics (PK). |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat, Study objectives were safety, response, survival, and pharmacokinetics (PK). |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | interstitial lung disease was excluded, and treatment resumed with steroid cover |
Clinical Primary efficacy | 60% |
Clinical PFS | 86.6 |
Clinical OS | 98.3 |
Clinical Result source | ClinicalTrials.gov NCT00712582 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 13일
현재 선택: 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | |
|---|---|
Overview Program | Liposomal doxorubicin |
Overview Company | Palleos Healthcare GmbH |
Overview Modality | ADC |
Overview Target | Breast Neoplasms |
Overview Indication | Lymphoproliferative Disorder; HHV-8 |
Overview Phase | PHASE_3 |
Overview Status | RECRUITING |
MoA Mechanism | , Clinical and Translational Science |
MoA Biomarker | biomarkers of liposomal doxorubicin-induced hypersensitivity in breast cancer: A pilot study |
PK/PD Half-life | 3 h |
PK/PD Species | Mouse, Rat, Study objectives were safety, response, survival, and pharmacokinetics (PK). |
PK/PD Animal (cat.) | Mouse, Rat |
PK/PD Experiment | pharmacokinetic |
Toxicology Species | Mouse, Rat, Study objectives were safety, response, survival, and pharmacokinetics (PK). |
Toxicology Animal (cat.) | Mouse, Rat |
Toxicology Major finding | interstitial lung disease was excluded, and treatment resumed with steroid cover |
Clinical Primary efficacy | 60% |
Clinical PFS | 86.6 |
Clinical OS | 98.3 |
Clinical Result source | ClinicalTrials.gov NCT00712582 |
Clinical Data Tier / Score | A · 50 |
Clinical Program phase | PHASE_3 |
Clinical Clinical sync | 2026년 7월 9일 (5일 전) |
추천 비교
추천 비교